NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Rhea-AI Summary

NewAmsterdam Pharma will present new clinical and preclinical data for its drug obicetrapib at the 93rd European Atherosclerosis Society Congress in Glasgow. The presentations include results from the BROADWAY and TANDEM Phase 3 trials, focusing on the drug's effectiveness in treating hypercholesterolemia.

Key presentations will highlight the fixed-dose combination of obicetrapib with ezetimibe for LDL-C reduction and the drug's safety profile in high cardiovascular risk patients. Additional sessions will cover obicetrapib's impact on atherosclerosis, vascular inflammation, and its effects when combined with moderate-dose statins.

The congress, scheduled for May 4-7, 2025, will feature multiple presentations across different sessions, including late-breaker oral presentations, poster networking sessions, and workshops. The research demonstrates obicetrapib's potential as a novel, oral, low-dose therapy for patients with elevated LDL-C who don't respond well to existing treatments.

Positive

• Multiple Phase 3 clinical trial data presentations (BROADWAY and TANDEM) showcasing obicetrapib's efficacy
• Positive preclinical data showing obicetrapib reduces atherosclerosis and vascular inflammation
• Demonstrated efficacy of obicetrapib in combination with ezetimibe and moderate-dose statins
• Development of a novel oral, low-dose therapy targeting a significant market (hypercholesterolemia)
• Strong scientific validation with multiple presentations at major industry conference (EAS Congress)

Negative

• None.

News Market Reaction

+3.13%

1 alert

+3.13% News Effect

On the day this news was published, NAMS gained 3.13%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers

NAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 93^rd Congress, taking place on May 4-7, 2025 in Glasgow, UK.

Late-breaker oral presentation details are as follows:

Title: Fixed-Dose Combination of Obicetrapib and Ezetimibe for LDL-C Reduction: A Phase 3 Randomized Trial
Session Name: Late Breaker Session: Clinical
Oral Presentation Date and Time: Wednesday, May 5, 2025, 12:00-12:15 PM BST (7:00-7:15 AM ET)
Location: William Harvey Hall

Title: Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Session Name: Late Breaker Session: Clinical
Oral Presentation Date and Time: Wednesday, May 5, 2025, 12:15-12:30 PM BST (7:15-7:30 AM ET)
Location: Will Harvey Hall

Additional session details are as follows:

Title: Obicetrapib Reduces Atherosclerosis and Vascular Inflammation, Mainly by Reducing Non-HDL Cholesterol, Improves Lesion Stability and Adds to the Beneficial Effects of Ezetimibe
Session Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and Outcomes
Presentation Date and Time: Monday, May 5, 2025, 1:58-2:05 PM BST (8:58-9:05 AM ET)
Location: Station 7

Title: Obicetrapib Alone and in Combination with Ezetimibe Increases Reverse Cholesterol Transport and Does Not Affect VLDL Production
Session Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and Outcomes
Presentation Date and Time: Monday, May 5, 2025, 2:05-2:12 PM BST (9:05-9:12 AM ET)
Location: Station 7

Title: Low-Dose Obicetrapib Significantly Increases Concentrations of Lipophilic Antioxidants, ApoE, and S1P in HDL Subfractions
Session Name: SaaG Session: Lipid Lowering Therapies and Advances in Vascular Therapeutics
Presentation Date and Time: Monday, May 5, 2025, 2:19-2:26 PM BST (9:19-9:26 AM ET)
Location: Station 4

Title: Obicetrapib Significantly Increases Plasma and High-Density Lipoprotein (HDL) Levels of Lipophilic Antioxidants
Session Name: SaaG Session: Lipoprotein Dynamics: HDL to Remnants
Presentation Date and Time: Monday, May 5, 2025, 3:17-3:24 PM BST (10:17-10:24 AM ET)
Location: Station 3

Title: Efficacy and Safety of Combination Obicetrapib with Moderate-Dose Statins
Session Name: Poster Networking Sessions
Presentation Date and Time: Monday, May 5 & Tuesday, May 6, 2025, 5:20 - 6:50 PM BST (12:17-1:24 PM ET)
Location: Poster Board #246, Exhibition Hall

Title: Safety and Efficacy of Cholesteryl Ester Transfer Protein Inhibition: From Genetics to Outcome Trials
Session Name: Workshop: New risk factors for atherosclerotic disease
Presentation Date and Time: Wednesday, May 7, 2025, 12:20 -12:30 PM BST (7:17-8:24 AM ET)
Location: James Black Hall

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact

Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact

Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com

Investor Contact

Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

What new clinical trials is NewAmsterdam Pharma (NAMS) presenting at EAS Congress 2025?

NewAmsterdam Pharma is presenting new data from BROADWAY and TANDEM Phase 3 clinical trials at the EAS Congress in Glasgow, focusing on obicetrapib's effects on lipid and lipoprotein biomarkers. The presentations include fixed-dose combination studies with ezetimibe and safety data in high cardiovascular risk patients.

When and where is NewAmsterdam Pharma (NAMS) presenting at EAS Congress 2025?

NewAmsterdam Pharma is presenting at the 93rd EAS Congress in Glasgow, UK, from May 4-7, 2025. Key presentations are scheduled for May 5, 2025, with late-breaker sessions starting at 12:00 PM BST in the William Harvey Hall.

What are the main benefits of obicetrapib shown in NewAmsterdam (NAMS) latest trials?

The trials show obicetrapib reduces atherosclerosis and vascular inflammation, increases reverse cholesterol transport, and significantly increases concentrations of lipophilic antioxidants. It's being developed as a novel, oral, low-dose therapy for patients with elevated LDL-C.

How does NewAmsterdam's (NAMS) obicetrapib work with other cholesterol medications?

Studies show obicetrapib works effectively in combination with ezetimibe and moderate-dose statins. The research demonstrates combined therapy benefits, particularly in LDL-C reduction, without affecting VLDL production.

What patient populations are targeted in NewAmsterdam's (NAMS) obicetrapib trials?

The trials focus on patients at risk of cardiovascular disease with elevated LDL-C levels, particularly those for whom existing therapies are not sufficiently effective or well-tolerated. This includes specific studies on high cardiovascular risk patients.